26 filings
6-K
BLTE
Belite Bio, Inc
3 Sep 24
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
8:00am
6-K
BLTE
Belite Bio, Inc
9 Aug 24
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
4:30pm
6-K
BLTE
Belite Bio, Inc
13 May 24
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
9:57pm
6-K
BLTE
Belite Bio, Inc
25 Apr 24
Belite Bio Announces $25 Million Registered Direct Offering
9:02pm
6-K
BLTE
Belite Bio, Inc
22 Mar 24
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
8:00am
6-K
ym025
11 Mar 24
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
9:59pm
6-K
i9fwk
11 Mar 24
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
8:51pm
6-K
zyl5j
13 Nov 23
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
8:20pm
6-K
ctp3du6xx8eky 6tw07e
6 Nov 23
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
8:00am
6-K
3yuh83wotpey5 jj6o
9 Aug 23
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
6:06am
6-K
0fw9wn
24 Jul 23
Belite Bio Completes Enrollment in Pivotal Global Phase 3
6:07am
6-K
y3s4bc ewt81z
16 Jun 23
Current report (foreign)
4:36pm
6-K
9grxl6rfz4
30 May 23
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
9:55pm
6-K
o4uhulu
30 May 23
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
4:01pm
6-K
aw6u2 eor
10 May 23
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
8:00pm
6-K
76w67261xa1
25 Apr 23
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
4:30pm
6-K
4dolyq16f s9
31 Mar 23
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
8:14pm
6-K
2a6587
13 Dec 22
Current report (foreign)
4:01pm
6-K
a64z2rpr29guodkvf4i
18 Nov 22
Current report (foreign)
8:00am
6-K
3rxf zi5q1hc30097k
3 Oct 22
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
6:02am